News
UCSF Receives $20 Million to Study New Tobacco Products
UC San Francisco has been awarded a five-year, $20 million grant from the U.S. Food and Drug Administration and the National Institutes of Health to study the impacts of new and emerging tobacco products, including e-cigarettes and heated tobacco products (HTPs), which heat tobacco without
Q&A with Mike Rabow, MD, Director of the HDFCCC Symptom Management Service
In the 13 years since Mike Rabow, MD, established the Symptom Management Service at the UCSF Helen Diller Family Comprehensive Cancer Center, with the support of Peter Carroll, MD, Gerri Shields, and the Mount Zion Health Fund, the specialty palliative care program has grown into one of largest in
'ImmunoX' Initiative a Radical Collaboration Across UCSF
UC San Francisco is launching the Bakar ImmunoX Initiative, an innovative research program that will promote collaborative, cutting-edge research and data sharing to catalyze discoveries about the central role of the immune system in human health and harness its power to treat a wide range of
UCSF Researchers Identify Unique Genetic Alterations in Brain Tumors Occurring After Radiation
For many common childhood cancers, radiation therapy can be an effective, even curative, treatment. However, long-term survivors are at risk for developing new, or secondary, cancers as a consequence of radiation, sometimes decades later. Children with cancers like medulloblastoma and
Scientists Map Interactions between Head and Neck Cancer and HPV Virus
Human papillomavirus (HPV) is widely known to cause nearly all cases of cervical cancer. However, you might not know that HPV also causes 70 percent of oropharyngeal cancer, a subset of head and neck cancers that affect the mouth, tongue, and tonsils. Although vaccines that protect against HPV
Researchers Unlock Secret of Deadly Brain Cancer's "Immortality"
Glioblastoma characterized by "palisading necrosis" (red). Credit: Costello Lab/UCSF. UC San Francisco researchers have discovered how a mutation in a gene regulator called the TERTpromoter — the third most common mutation among all human cancers and the most common mutation in the deadly brain
Mutations, Drugs Drive Cancer by Blurring Growth Signals
Genetic mutations in a form of non–small cell lung cancer (NSCLC) may drive tumor formation by blurring cells’ perception of key growth signals, according to a new laboratory study published Aug. 31, 2018, in Science. The research, led by UC San Francisco researchers, could have important